Clinical Trials Directory

Trials / Completed

CompletedNCT05770856

Clinical Metagenomic of Post-traumatic Infections

Clinical Metagenomic Next-Generation Sequencing for Microbial Infections in Trauma

Status
Completed
Phase
Study type
Observational
Enrollment
25 (actual)
Sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Treatment of fracture related infection is challenging and often lead to failure in such situation that carry a high health cost burden. These infections are often polymicrobial, making the identification of all involved microorganisms a major concern to provide tailored antibiotic treatment. Culture-independent methods are needed to better represent the microbial diversity of infected wounds. Metagenomic sequencing might lead to an accurate microbiome characterization in infected trauma-related wound. Preliminary studies have reported results of metagenomic sequencing in diabetic foot infection but data focusing on non-diabetic infected patients are scarce. The impact of post-traumatic infected wound microbiome needs to be assessed, with regards to bacterial abundance, diversity including at the strain level and functional genes, along with their longitudinal evolution and association with clinical outcomes.

Detailed description

DNA will be extracted from samples carried out during surgical procedures. Different extraction protocols will be assessed to determine the best to be used for this type of tissue samples. Purified DNA will be quantified using the Qubit dsDNA High-Sensitivity Assay Kit (Invitrogen). The quality of the fragment length will be estimated with the DNA high-sensitivity kit in the 2100 Bioanalyzer (Agilent Technologies). DNA sequencing will be performed with Oxford Nanopore Technologie devices: MinIONTM and GridIONTM. Another sequencing of the same samples will be performed on the MiSeq after libraries preparation using the NexteraXT DNA Library Preparation Kit (Illumina). Sequenced OTU from both sequencing methods will be confronted at different taxonomic ranks and compared with conventional routine method results (bacterial culture). A functional analysis of sequences will be done to identify potential genes associated with clinical outcome.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTMetagenomic sequencingSamples shall be submitted to high throughput sequencing using both illumine MiSeq and Oxford Nanopore Technologies.

Timeline

Start date
2023-04-27
Primary completion
2023-07-15
Completion
2023-07-15
First posted
2023-03-16
Last updated
2024-07-29

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05770856. Inclusion in this directory is not an endorsement.